CJC-1295 (no DAC) is a modified growth hormone-releasing hormone (GHRH 1–29) analog designed for shorter-acting activity in research settings. Without the Drug Affinity Complex (DAC), this version is commonly studied for its more controlled and transient signaling profile, making it useful in models examining natural hormone release patterns.
 
This peptide is frequently investigated in laboratory environments focused on growth hormone release dynamics, IGF-1 signaling, and endocrine system regulation.
 
Mechanism of Action
 
CJC-1295 (no DAC) functions as a GHRH receptor agonist, stimulating receptors involved in growth hormone regulation.
 
Research has explored associations with:
 
• Increased growth hormone (GH) release
• Elevated IGF-1 signaling activity
• Support for physiologic, pulsatile hormone release patterns
• Shorter duration of activity compared to DAC-modified variants
 
Due to the absence of DAC, this peptide demonstrates faster clearance and more controlled signaling duration in research models.
 
Research Applications
 
CJC-1295 (no DAC) is commonly studied in laboratory settings involving:
• Growth hormone and IGF-1 pathway research
• Endocrine system signaling studies
• Pulsatile hormone release modeling
• Metabolic regulation models
 
Product Specifications
 
• Peptide Content: 5mg Lyophilized Peptide
• Type: GHRH (1–29) Analog (No DAC)
• Purity: ≥98% verified by HPLC testing
• Form: Lyophilized peptide powder
• Storage: Store lyophilized peptide frozen. After reconstitution, maintain refrigerated conditions (2–8°C) and avoid repeated freeze-thaw cycles.
 
Research Use Notice
 
This product is intended strictly for laboratory research and analytical purposes only.
 
• Not for human consumption
• Not for veterinary use
• Not intended for ingestion, injection, or bodily administration
• Not a drug, food, cosmetic, or dietary supplement
 
All information provided is for educational and scientific reference purposes only.